Intense circulating neutrophilia would be safe, based on the clinical reports previously cited and some older reports on constitutive neutrophilia [32, 33] and certainly the pharmaceutical companies that market G-CSF report no problems to arise at 100 × 109 PMNs/L, observed in at least 2% of the patients treated for neutropenia ([34]).Other reports in which G-CSF has been used to raise PMNs levels 56,000 ± 16,000/mm3 suggest this not to be associated with adverse circulatory or cardiovascular effects [35]. Here, CSF3 is linked to neutropenia.